

Joakim Nyberg

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/10430986/publications.pdf>

Version: 2024-02-01

16
papers

905
citations

1163117

8
h-index

940533

16
g-index

17
all docs

17
docs citations

17
times ranked

604
citing authors

#	ARTICLE	IF	CITATIONS
1	Population Pharmacokinetic Modeling and Optimal Sampling Strategy for Bayesian Estimation of Amikacin Exposure in Critically Ill Septic Patients. <i>Therapeutic Drug Monitoring</i> , 2010, 32, 749-756.	2.0	594
2	Methods and software tools for design evaluation in population pharmacokineticsâ€“pharmacodynamics studies. <i>British Journal of Clinical Pharmacology</i> , 2015, 79, 6-17.	2.4	65
3	PopED: An extended, parallelized, nonlinear mixed effects models optimal design tool. <i>Computer Methods and Programs in Biomedicine</i> , 2012, 108, 789-805.	4.7	61
4	Rapid Sample Size Calculations for a Defined Likelihood Ratio Test-Based Power in Mixed-Effects Models. <i>AAPS Journal</i> , 2012, 14, 176-186.	4.4	39
5	Simultaneous optimal experimental design on dose and sample times. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 2009, 36, 125-145.	1.8	34
6	Population pharmacokinetics of edoxaban in patients with symptomatic deepâ€“vein thrombosis and/or pulmonary embolismâ€“the Hokusaiâ€“VTE phase 3 study. <i>British Journal of Clinical Pharmacology</i> , 2015, 80, 1374-1387.	2.4	18
7	Application of the Optimal Design Approach to Improve a Pretransplant Drug Dose Finding Design for Cyclosporin. <i>Journal of Clinical Pharmacology</i> , 2012, 52, 347-360.	2.0	16
8	A Pharmacokinetic-Pharmacodynamic Model of Morphine Exposure and Subsequent Morphine Consumption in Postoperative Pain. <i>Pharmaceutical Research</i> , 2016, 33, 1093-1103.	3.5	13
9	Trial Treatment Length Optimization With an Emphasis on Disease Progression Studies. <i>Journal of Clinical Pharmacology</i> , 2009, 49, 323-335.	2.0	9
10	Optimal Experimental Design for Assessment of Enzyme Kinetics in a Drug Discovery Screening Environment. <i>Drug Metabolism and Disposition</i> , 2011, 39, 858-863.	3.3	7
11	Optimizing disease progression study designs for drug effect discrimination. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 2013, 40, 587-596.	1.8	6
12	Inter occasion variability in individual optimal design. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 2015, 42, 735-750.	1.8	6
13	The effect of Fisher information matrix approximation methods in population optimal design calculations. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 2016, 43, 609-619.	1.8	4
14	Analysis of opioid consumption in clinical trials: a simulation based analysis of power of four approaches. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 2017, 44, 325-333.	1.8	4
15	Ethically Attractive Doseâ€“Finding Designs for Drugs With a Narrow Therapeutic Index. <i>Journal of Clinical Pharmacology</i> , 2012, 52, 29-38.	2.0	3
16	Optimal clinical trial design based on a dichotomous Markov-chain mixed-effect sleep model. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 2014, 41, 639-654.	1.8	1